Neoplasms
Conditions
Brief summary
Evaluation of maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBW 2992, pharmacodynamic modulation of biomarkers, correlation of Epidermal Growth Factor Receptor (EGFR) and Human EGF-like Receptor number 2 (HER2) immunohistochemical status with objective tumour responses
Interventions
DRUGBIBW 2992
escalating doses
Sponsors
Boehringer Ingelheim
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumors, of types historically known to express EGFR and/or HER2, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment * Age 18 years or older * Life expectancy of at least three (3) months * Written informed consent given that is consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines * Eastern Cooperative Oncology Group (ECOG) performance score 0, 1, or 2 * Patients must have resolution of prior chemo-, hormone, immuno-, or radiotherapy-related toxicities to CTC Grade \< 1 * Patients have to be recovered from previous surgery * Paraffin-embedded tumor material must be accessible for analysis of EGFR and HER2-status. * The additional 12 patients that were to be recruited at the MTD also had to fulfill the following criterion: Measurable tumor deposits (RECIST: Response Evaluation Criteria in Solid Tumors) by one or more techniques (X-ray, CT, MRI)
Exclusion criteria
* Active infectious disease * Gastrointestinal disorders that might interfere with the absorption of the study drug or chronic diarrhea * Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol * Brain metastases requiring therapy as based on clinical symptoms * Impaired cardiac left ventricular function with resting ejection fraction CTC Grade ≥ 1 * Absolute neutrophil count (ANC) less than 1500 / mm3 * Platelet count less than 100 000 / mm3 * Bilirubin greater than 1.5 mg / dl (\> 26 μmol / L, SI unit equivalent) * Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal) * Serum creatinine greater than 1.5 mg / dl (\> 132 μmol / L, SI (Systeme International) unit equivalent) * Women and men who are sexually active and unwilling to use a medically acceptable method of contraception * Pregnancy or breast-feeding * Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (excluding LHRH agonists, other hormones taken for breast cancer, or bisphosphonates) or participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study * Patients unable to comply with the protocol * Active alcohol or drug abuse RETREATMENT CRITERIA The patient may be eligible for re-treatment after the previous course finished. The patient will not be eligible if the following criteria are met. * Patients with clinical signs of disease progression or if an X-ray, CT or MRI was done and the test showed progressive disease * Cardiac left ventricular function CTC Grade ≥ 2 at any time during the previous course * Patients fulfilling any of the
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum tolerated dose (MTD) | up to 28 months |
| Incidence and intensity of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) associated with increasing doses of BIBW 2992 | up to 28 months |
Secondary
| Measure | Time frame |
|---|---|
| Minimum measured plasma concentration (Cmin) for different time points | up to 384 hours after first drug administration |
| Maximum measured plasma concentration (Cmax) for different time points | up to 384 hours after first drug administration |
| Time from dosing to the minimum plasma concentration (tmin) for different time points | up to 384 hours after first drug administration |
| Time from dosing to the maximum plasma concentration (tmax) for different time points | up to 384 hours after first drug administration |
| Terminal half-life (t1/2) for different time points | up to 384 hours after first drug administration |
| Mean residence time after oral administration (MRTpo) for different time points | up to 384 hours after first drug administration |
| Area under the plasma concentration-time curve (AUC) for different time points | up to 384 hours after first drug administration |
| Apparent volume of distribution during the terminal phase (Vz/F) for different time points | up to 384 hours after first drug administration |
| Accumulation ratio (RA) | up to 384 hours after first drug administration |
| Modulation of biomarker (EGFR, p-EGFR, p-MAPK (mitogen-activated protein kinase), p-Akt, Ki-67, p-27KIP1) in skin biopsies prior to administration of BIBW 2992 and at the end of the first treatment period | Baseline and day 14 |
| Modulation of biomarker (EGFR, p-EGFR, HER2, p-MAPK, p-Akt, Ki-67, p-27KIP1) in tumor biopsies prior to administration of BIBW 2992 and at the end of the first treatment period in 6 or more patients treated at the MTD | Baseline and day 14 |
| Objective tumor responses | every 8 weeks up to 28 months |
| Correlation of EGFR, HER2, estrogen receptor and progesterone receptor immunohistochemical status as based on tumor biopsies or excisions obtained prior to this trial with objective tumor responses | up to 28 months |
| Apparent clearance (CL/F) for different time points | up to 384 hours after first drug administration |
| Predose plasma concentration (Cpre) for different time points | Day 8 and 14 |
Outcome results
None listed